- Home
- NWFL vs CRGX Comparison
NWFL vs CRGX Comparison
Compare NWFL & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWFL
- CRGX
- Stock Information
- Founded
- NWFL 1870
- CRGX 2021
- Country
- NWFL United States
- CRGX United States
- Employees
- NWFL N/A
- CRGX N/A
- Industry
- NWFL Major Banks
- CRGX
- Sector
- NWFL Finance
- CRGX
- Exchange
- NWFL Nasdaq
- CRGX Nasdaq
- Market Cap
- NWFL 180.0M
- CRGX 180.4M
- IPO Year
- NWFL 1998
- CRGX 2023
- Fundamental
- Price
- NWFL $23.01
- CRGX $4.64
- Analyst Decision
- NWFL Buy
- CRGX Hold
- Analyst Count
- NWFL 2
- CRGX 7
- Target Price
- NWFL $29.50
- CRGX $4.67
- AVG Volume (30 Days)
- NWFL 36.0K
- CRGX 653.7K
- Earning Date
- NWFL 04-17-2025
- CRGX 05-13-2025
- Dividend Yield
- NWFL 5.51%
- CRGX N/A
- EPS Growth
- NWFL N/A
- CRGX N/A
- EPS
- NWFL 0.14
- CRGX N/A
- Revenue
- NWFL $50,378,000.00
- CRGX N/A
- Revenue This Year
- NWFL $78.94
- CRGX $58.18
- Revenue Next Year
- NWFL $7.21
- CRGX N/A
- P/E Ratio
- NWFL $163.45
- CRGX N/A
- Revenue Growth
- NWFL N/A
- CRGX N/A
- 52 Week Low
- NWFL $21.25
- CRGX $3.00
- 52 Week High
- NWFL $34.50
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- NWFL 44.36
- CRGX 59.08
- Support Level
- NWFL $21.25
- CRGX $3.58
- Resistance Level
- NWFL $24.00
- CRGX $4.17
- Average True Range (ATR)
- NWFL 1.13
- CRGX 0.26
- MACD
- NWFL 0.03
- CRGX 0.12
- Stochastic Oscillator
- NWFL 49.30
- CRGX 92.98
About NWFL Norwood Financial Corp.
Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.